𝗘𝗦𝗠𝗢 𝟮𝟬𝟮𝟲 𝗧-𝗖𝗘𝗟𝗟 𝗘𝗡𝗚𝗔𝗚𝗘𝗥𝗦: 𝗗𝗟𝗟𝟯, 𝗣𝗥𝗔𝗠𝗘, 𝗧𝗔𝗥𝗚𝗘𝗧 𝗗𝗘𝗡𝗦𝗜𝗧𝗬 & 𝗡𝗘𝗫𝗧-𝗚𝗘𝗡 𝗕𝗜𝗦𝗣𝗘𝗖𝗜𝗙𝗜𝗖𝗦

The T-cell engager (TCE) landscape in solid tumours reached a pivotal turning point at ESMO 2026. This video provides a comprehensive breakdown of clinical progress, emerging molecular architectures, antigen density dynamics, and strategic developments across major target classes including DLL3, PRAME, ENPP3, and EGFR. Executive Overview & Clinical Takeaways T-cell engagers are transitioning from proof-of-concept validation to sophisticated molecular engineering designed to solve selective, durable, and predictable T-cell activation in solid tumours. Major clinical highlights and strategic themes from ESMO 2026 include: • DLL3 Benchmark Validation: Amgen's Tarlatamab established Phase 3 overall survival validation in extensive-stage small-cell lung cancer (ES-SCLC), demonstrating a median OS of 21.1 months versus 12.7 months in the comparator group. • Biomarker-Driven DLL3 Competitors: Boehringer Ingelheim's Obrixtamig (BI 764532) Phase 1b DAREON-7 trial showed higher response rates in DLL3-high neuroendocrine carcinomas, proving antigen density as a critical determinant of response. Zelgen and AbbVie's Alveltamig (ZG006) introduced a biparatopic trispecific approach (DLL3 x DLL3 x CD3) to maximize binding avidity. • Intracellular Antigen Targeting (PRAME/pHLA): Immatics' IMA402 demonstrated that TCR-based engagers (TCERs) can target intracellular tumour proteins presented via HLA-A*02:01, expanding the targetable tumour landscape beyond cell-surface proteins. • Density-Dependent Selectivity (2+1 Formats): Xencor's XmAb819 utilized a bivalent ENPP3 x CD3 design (2+1 architecture) in clear-cell renal cell carcinoma to exploit density differences between tumour and normal tissues, aiming to widen the therapeutic window. • Protease-Activated Masking: ShiMai Pharma and CentryMed's CMDE005 demonstrated a protease-activated, CD3-masked EGFR x CD3 construct engineered to remain inactive in systemic circulation and activate selectively inside the tumour microenvironment to prevent cytokine release syndrome (CRS). Video Chapters & Timestamps 00:00 - Introduction: The Solid Tumour T-Cell Engager Frontier at ESMO 2026 01:45 - DLL3 Clinical Benchmark: Tarlatamab Phase 3 OS Survival Data 04:20 - Next-Gen DLL3 Strategies: Obrixtamig Biomarker Data & Alveltamig Biparatopic Design 07:10 - Targeting Intracellular Antigens: Immatics IMA402 & PRAME HLA-A*02:01 TCER Platform 09:55 - Engineering Selectivity: XmAb819 2+1 Bivalent ENPP3 Engagement 12:15 - Tumour Microenvironment Activation: CMDE005 Protease-Masked EGFR TCE 14:40 - Strategic Analysis: Target Abundance, Immune Synapse, and the Future Window 17:30 - Key Questions for Investors and Developers & Final Takeaways #TCellEngagers #ESMO2026 #Immunotherapy #Oncology #Biotech #Bispecifics #CancerResearch #PharmaStrategy